Diagnostic Value of Oral Prednisolone Test for Rheumatoid Arthritis (TryCort)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Rheumatoid arthritis is an inflammatory joint disease often leading to progressive joint destruction. To prevent disability caused by inflamed joints early diagnosis is important. Early diagnosis might be a challenge because the diagnosis is mostly based on clinical signs like swelling of small joints. In clinical practice a therapy with prednisolone is started although the patients do not have an exact diagnosis. In this cases the prednisolone might serve as a diagnostic test for an inflammatory process.
The objective of this study is to investigate the diagnostic value of oral prednisolone test for rheumatoid arthritis.
| Condition | Intervention | Phase |
|---|---|---|
|
Rheumatoid Arthritis |
Drug: Prednisolone |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Diagnostic |
| Official Title: | Phase II/III Study of Oral Prednisolone Test in Patients With Rheumatoid Arthritis |
- Rate of true diagnosis of rheumatoid arthritis after positive prednisolone test [ Time Frame: 3 months ] [ Designated as safety issue: No ]Positive prednisolone test: change of more than 40% (on a NRS 0-100%) in painful joints after 3 days of therapy with prednisolone 20 mg/d
- Rate of true negative diagnosis of rheumatoid arthritis after positive prednisolone test [ Time Frame: 3 months ] [ Designated as safety issue: No ]Positive prednisolone test: change of more than 40% (on a NRS 0-100%) in painful joints after 3 days of therapy with prednisolone 20 mg/d
- Negative predictive value [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- Positive predictive value [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- clinical characteristics of patients with early RA [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- change of disease activity [ Time Frame: 3 months ] [ Designated as safety issue: No ]assessed with DAS-28
- change of functioning [ Time Frame: 3 months ] [ Designated as safety issue: No ]assessed with HAQ
| Estimated Enrollment: | 130 |
| Study Start Date: | February 2012 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | August 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Prednisolone
Patients with suspicious of rheumatoid arthritis will undergo a prednisolone test with 20 mg per day for 3 days after 2 days of therapy with paracetamol 500 mg twice for 2 days.
|
Drug: Prednisolone
prednisolone 20 mg once a day per os for 3 subsequent days
Other Name: glucocorticoids
|
Detailed Description:
Rheumatoid arthritis is with a prevalence of 2% an important inflammatory joint disease which often leads to impaired functioning and reduced quality of life. Early diagnosis is an important step forward to prevent progressive joint destruction. The classification criteria for rheumatoid arthritis published in 2010 are based on clinical signs (such as swelling) and laboratory findings (such as rheumatoid factor) (Aletaha D 2010). Because its diagnosis is based on clinical signs the early diagnosis for rheumatoid arthritis might be a challenge in daily clinical care.
In clinical practice a therapy with prednisolone is started although the patients do not have an exact diagnosis. It has been shown that the start of early low-dose prednisolone decreases the rate of joint destruction after two years of therapy (Kirwan JR 1995, Wassenberg S 2005). Thus, prednisolone might have effects comparable to that of disease-modifying antirheumatic drugs.
The objective of this study is to investigate the diagnostic value of oral prednisolone test for rheumatoid arthritis. The hypothesis is that in patients with rheumatoid arthritis the prednisolone test will be positive in 80% of the patients whereas positive in just 20% of patients with osteoarthritis of the hand. Positive prednisolone test is defined as a 30% improvement of the symptoms in finger and wrist on a numeric rating scale from 0-100.
Patients with suspicious of rheumatoid arthritis will undergo a prednisolone test with 20 mg per day for 3 days after 2 days of therapy with paracetamol 500 mg twice. After this period the patients will be asked to rate their benefit in improving pain and reducing swelling of wrist and finger joints on a numeric rating scale (0-100 % improvement in steps of 20%). A positive response In addition, demographics and clinical parameter including the compound measure for disease activity DAS-28 will be collected. A patient with a positive prednisolone test will receive standard care for rheumatoid arthritis onward. Patients with a negative prednisolone test will receive standard care for hand and finger osteoarthritis onward. At week 12 all patients will be seen again to reassess the former diagnosis.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- pain in wrist and fingers without known diagnosis since more than 6 weeks, minimum of pain on a numerical rating scale 4 (out of 10)
Exclusion Criteria:
- rheumatoid arthritis
- psoriatic arthritis
- psoriasis vulgaris
- vasculitis
- gouty arthritis
- Current glucocorticoidmedication
Contacts and Locations
More Information
Publications:
| Responsible Party: | Prof. Dr. med. Jürgen Braun, Professor of Rheuamtology, Rheumazentrum Ruhrgebiet |
| ClinicalTrials.gov Identifier: | NCT01395251 History of Changes |
| Other Study ID Numbers: | TryCort |
| Study First Received: | July 12, 2011 |
| Last Updated: | May 23, 2012 |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Keywords provided by Rheumazentrum Ruhrgebiet:
|
rheumatoid arthritis diagnosis sensitivity glucocorticoids |
Additional relevant MeSH terms:
|
Arthritis Arthritis, Rheumatoid Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Connective Tissue Diseases Autoimmune Diseases Immune System Diseases Glucocorticoids Prednisolone Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone hemisuccinate Prednisolone phosphate Methylprednisolone acetate |
Prednisolone acetate Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions Anti-Inflammatory Agents Therapeutic Uses Antineoplastic Agents, Hormonal Antineoplastic Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Central Nervous System Agents Gastrointestinal Agents Neuroprotective Agents |
ClinicalTrials.gov processed this record on May 23, 2013